COLLEGIUM PHARMACEUTICAL, INC(COLL)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

COLLEGIUM PHARMACEUTICAL, INC (COLL) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores COLL at 62.7/100 on a 32-signal composite quality model, placing it at rank #692 of 2,962 stocks — the top 25% of the AI-ranked universe. COLL scores in the top quartile across earnings quality (97.4), free cash flow (91.0), revenue growth (77.7). Areas of concern include institutional flow (23.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 24.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), COLLEGIUM PHARMACEUTICAL, INC reports quarterly revenue of $199.9M, net income of $-15.1M, free cash flow of $70.8M. Top institutional holders of COLL by reported 13-F value include BlackRock, Jupiter Topco, Invesco Ltd., based on the most recent SEC filings. COLL trades on the Nasdaq exchange and files with the SEC under CIK 1267565. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate COLL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for COLLEGIUM PHARMACEUTICAL, INC directly from SEC EDGAR.